Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth and Progenics set to initiate oral methylnaltrexone trial

Wyeth and Progenics set to initiate oral methylnaltrexone trial

17th October 2007

Wyeth Pharmaceuticals and Progenics Pharmaceuticals have announced that they are set to initiate two four-week phase II trials to evaluate daily dosing of oral methylnaltrexone.

The oral formulation is indicated for treatment in patients with chronic, non-malignant pain who are being treated with opioids and are experiencing opioid-induced constipation (OIC).

The trials will be conducted by Wyeth and will see 120 patients participating in over 40 sites.

Patients who currently receive opioids to help manage chronic pain and have OIC will take part in the trial.

A different oral formulation of methylnaltrexone will be used in each study including a formulation that displayed positive preliminary results in a phase I study in July 2007.

Wyeth and Progenics have announced their plan to assess the safety and dose-response of oral methylnaltrexone as measured by the occurrence of spontaneous bowel movements during the treatment period

Both studies are expected to take six months and will assist in determining the formulation and doses to be used in phase III studies.

This week, Wyeth Pharmaceuticals announced positive study data for desvenlafaxine, with menopausal patients receiving the compound showing a reduction in moderate to severe vasomotor symptoms compared to those receiving a placebo.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.